asfotase alfa
Selected indexed studies
- Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. (Mol Genet Metab, 2017) [PMID:28888853]
- ** (, 2023) [PMID:40258101]
- ** (, 2017) [PMID:29356465]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. (2017) pubmed
- PMID:40258101 (2023) pubmed
- PMID:29356465 (2017) pubmed
- Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. (2019) pubmed
- Asfotase alfa for hypophosphatasia. (2018) pubmed
- Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. (2019) pubmed
- Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval. (2025) pubmed
- Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review. (2024) pubmed
- Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. (2025) pubmed
- Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia. (2016) pubmed